What Is GLP-1? The Hormone Behind the Drug Class

This page lives in the PlexusDx Education Hub, where we unpack GLP-1 biology, weight-management options, and the genetic factors sitting beneath each choice. Open the Peptides & GLP-1 library.

Before GLP-1 was a drug class, it was a hormone your gut already makes. Understanding what glucagon-like peptide-1 does in the body clarifies why the medications built around it behave the way they do. This article defines the hormone, follows its actions, explains why it had to be engineered into a therapy, lists the approved compounds, and turns to the genetic pathway beneath.

GLP-1 the hormone, defined

Glucagon-like peptide-1 is an incretin hormone — a 30- to 31-amino-acid peptide released by enteroendocrine L-cells lining the small intestine whenever food arrives. Its job is to coordinate the body's response to a meal, linking what is eaten to how insulin, glucose, and appetite are managed in the minutes and hours that follow.

What native GLP-1 does

Once secreted, GLP-1 prompts glucose-dependent insulin release from pancreatic beta cells, suppresses glucagon from alpha cells, slows gastric emptying, and engages satiety circuits in the hypothalamus. Its natural half-life is only about two minutes, because the enzyme dipeptidyl peptidase-4 (DPP-4) degrades it almost as fast as it appears.

Why the hormone needed engineering

A two-minute signal is far too fleeting to build a therapy on. GLP-1 receptor agonist drugs are designed to resist DPP-4 breakdown, stretching the half-life from minutes to days or even weeks. They bind the same GLP-1 receptor as the native hormone and reproduce its downstream effects on insulin, glucagon, gastric emptying, and satiety. Tirzepatide-based compounds add agonism at the related GIP receptor.

The FDA-approved compounds as of April 2026

The approved class includes exenatide (Byetta, 2005; Bydureon), liraglutide (Victoza, 2010; Saxenda, 2014), dulaglutide (Trulicity, 2014), semaglutide (Ozempic, 2017; Rybelsus, 2019; Wegovy, 2021), and tirzepatide (Mounjaro, 2022; Zepbound, 2023; Zepbound expanded to obstructive sleep apnea, 2024). Rybelsus remains the only FDA-approved oral option.

Where the field is heading

Two investigational directions stand out. Retatrutide is a GIP/GLP-1/glucagon triple agonist with Phase 3 data; it is not FDA-approved and is not sold by PlexusDx. Orforglipron is an oral, non-peptide small-molecule GLP-1 receptor agonist in late-stage development. Both illustrate how the pathway keeps expanding beyond the original single-receptor design, and both underscore that the field is still moving quickly enough that today's roster is a snapshot rather than a finished list.

Where your genetics enter the conversation

Because these drugs act on a receptor system, natural genetic variation in that system matters. The receptor these drugs bind, GLP1R, varies from person to person in ways that influence receptor density and how efficiently the incretin signal travels downstream. Nearby, FTO shapes appetite regulation and where the body sets its adiposity baseline, MC4R governs satiety signaling inside the hypothalamus and total energy intake, and TCF7L2 is tied to insulin secretion and incretin response. GLP1R is the most direct upstream variable, influencing receptor density and incretin signaling efficiency.

None of these variants forecast how you will respond to a particular medication, and the analysis is not pharmacogenomic. What they do is describe the metabolic terrain a clinician is working within. The PlexusDx Precision Peptide Genetic Test reads 14 pathways, 49 peptides, 150+ genetic insights across FTO and MC4R, and TCF7L2 — pathway-level context you bring to a provider conversation, never a prediction of drug response or dose. It is the test before you invest idea applied to metabolic care.

PlexusDx offers GLP-1 receptor agonists through its Weight Management Protocols. For the drug-class angle, see GLP-1 Receptor Agonist; for the medications themselves, see GLP-1 Drugs.

The bottom line: GLP-1 is a natural gut hormone first and a drug class second. The medications succeed precisely because they extend a signal the body already trusts. Seeing the hormone, the engineering, and the receptor genetics together makes the whole category far easier to reason about than any single brand name.

Frequently Asked Questions

What does GLP-1 stand for?

GLP-1 stands for glucagon-like peptide-1. It is an incretin hormone secreted by intestinal L-cells after eating, and it prompts glucose-dependent insulin release, slows gastric emptying, and signals fullness to the brain. The GLP-1 receptor agonist drug class was built to mimic these natural effects.

Are GLP-1 agonists and GLP-1 inhibitors the same?

No — they are opposites. Agonists activate the GLP-1 receptor and reproduce the hormone's effects. There is no widely used class called "GLP-1 inhibitors" in current practice. DPP-4 inhibitors are a separate category that slows breakdown of native GLP-1 rather than activating the receptor directly.

Why is native GLP-1 so short-lived?

The enzyme DPP-4 degrades it within roughly two minutes of release, which is why the natural hormone cannot serve as a therapy on its own. Drugmakers engineered the receptor agonists specifically to resist that enzyme, extending the signal from minutes to days or weeks.

Does genetic testing tell me which GLP-1 to take?

No. The Precision Peptide Genetic Test does not predict which compound suits any individual. It analyzes pathway-level variants in FTO, and MC4R that shape baseline GLP-1 biology, offering context for a broader protocol conversation with a healthcare provider rather than a recommendation.

Keep exploring the PlexusDx Education Hub for more GLP-1 and metabolic-health explainers. Return to the Education Hub.